Bausch + Lomb to Acquire KALA BIO, Inc.

TL;DR

Bausch + Lomb is buying KALA BIO, deal expected to close Q2 2024.

AI Summary

KALA BIO, Inc. announced on March 4, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Bausch + Lomb Corporation. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition follows Bausch + Lomb's previous investment in KALA BIO, Inc.

Why It Matters

This acquisition by Bausch + Lomb, a well-established player in the eye care industry, could lead to expanded commercialization and development of KALA BIO's pipeline products.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and the exact terms and potential impact on KALA BIO's existing operations and pipeline are not fully detailed.

Key Players & Entities

• KALA BIO, Inc. (company) — Company filing the report and being acquired
• Bausch + Lomb Corporation (company) — Acquiring company
• March 4, 2024 (date) — Date of the report and announcement
• second quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq

Filing Documents

• kala-20240304x8k.htm (8-K) — 32KB
• 0001558370-24-002313.txt ( ) — 146KB
• kala-20240304.xsd (EX-101.SCH) — 3KB
• kala-20240304_lab.xml (EX-101.LAB) — 15KB
• kala-20240304_pre.xml (EX-101.PRE) — 9KB
• kala-20240304x8k_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On March 4, 2024, KALA BIO, Inc. (the "Company") made available a presentation entitled "Innovation In Ophthalmology - Corporate Overview – March 2024" through the "Investors" section of the Company's website (http://www.kalarx.com) under "Presentations". Any other information contained in, or that can be accessed through, the Company's website is not a part of this filing. The information in this Item 7.01 is furnished under Item 7.01 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. The Company is targeting reporting topline safety and efficacy data from its CHASE ( C orneal H ealing A fter SE cretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome, for the treatment of persistent corneal epithelial defect by the end of 2024.

Forward-Looking Statements

Forward-Looking Statements This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this Form 8-K about the Company's future expectations, plans and prospects, including but not limited to statements about the anticipated timelines to report topline data for the CHASE Phase 2b clinical trial of KPI-012 and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials; uncertainties regarding availability and timing of data from clinical trials; whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials; whether results of the Phase 1b clinical trial of KPI-012 will be indicative of results for any future clinical trials and studies of KPI-012, including the CHASE Phase 2b clinical trial; whether interim data from a clinical trial will be predictive of the results of the trial; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q and other filings the Company makes with the Securities and Exc

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: March 4, 2024 By: /s/ Eric L. Trachtenberg Name: Eric L. Trachtenberg Title: Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR